GDOC - ETF AI Analysis
Top Page
Goldman Sachs Future Health Care Equity ETF (GDOC)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Core Health Care Leaders
Several major holdings like Eli Lilly, Johnson & Johnson, UnitedHealth, Merck, Guardant Health, and Dexcom have shown strong year-to-date performance, helping support the ETF’s overall returns.
Focused Exposure to Health Care Theme
With most assets in the health care sector, the fund gives targeted access to companies benefiting from long-term trends in medical innovation and services.
Recent Performance Momentum
The ETF has delivered strong gains over the past one and three months, suggesting positive recent momentum in its portfolio.
Negative Factors
High Sector Concentration
Because the ETF is heavily concentrated in health care, investors are more exposed to downturns or policy changes affecting this single sector.
Limited Geographic Diversification
The fund is dominated by U.S. holdings with only small exposure to other countries, which reduces the benefits of global diversification.
Relatively High Expense Ratio
The ETF’s expense ratio is on the higher side for an index-style product, meaning more of the fund’s returns are used to cover fees.
GDOC vs. SPDR S&P 500 ETF (SPY)
AUM19.17M
RegionGlobal
Expense Ratio0.75%
Beta0.61
IssuerGoldman Sachs
Inception DateNov 09, 2021
Dividend Yield0.31%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume435
30 Day Avg. Volume427
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
43.94Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering41
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GDOC Summary
GDOC is the Goldman Sachs Future Health Care Equity ETF, focused on companies shaping the future of health care, especially health care technology. It doesn’t track a traditional index, but instead holds a handpicked mix of U.S. and global health firms, including well-known names like Eli Lilly and Johnson & Johnson, along with newer players in digital health, biotech, and medical devices. Someone might invest in GDOC for growth potential and to bet on long-term trends like telemedicine and advanced treatments. A key risk is that it’s heavily concentrated in health care stocks, so its price can swing more than the overall market.
How much will it cost me?The Goldman Sachs Future Health Care Equity ETF (GDOC) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care technology companies that require more research and expertise to select.
What would affect this ETF?The Goldman Sachs Future Health Care Equity ETF (GDOC) could benefit from increasing demand for health care technology, driven by advancements in telemedicine, biotech, and medical devices, as well as global aging populations requiring innovative solutions. However, it may face challenges from regulatory changes in the health care sector, fluctuating interest rates affecting growth-focused companies, and potential competition or setbacks in technological adoption. Its global exposure and focus on leading companies like Eli Lilly and Boston Scientific provide both opportunities and risks tied to the broader health care industry trends.
GDOC Top 10 Holdings
GDOC is leaning heavily into big, established health care names, with Merck and Johnson & Johnson doing much of the heavy lifting thanks to their rising, steady performance. Eli Lilly has been more mixed lately, but its longer-term strength still supports the fund’s story. On the techier side of health care, Agilent and Thermo Fisher are climbing, adding momentum from diagnostics and lab tools, while UnitedHealth and Dexcom have been lagging and occasionally dragging on returns. Overall, it’s a globally focused, health care–centric play with a tilt toward innovative, future-facing medicine.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.40% | $2.38M | $1.08T | 36.07% | 72 Outperform | |
| Johnson & Johnson | 8.27% | $1.58M | $617.01B | 35.72% | 78 Outperform | |
| Merck & Company | 7.40% | $1.42M | $356.01B | 61.79% | 80 Outperform | |
| UnitedHealth | 5.55% | $1.06M | $333.82B | 3.25% | 72 Outperform | |
| Guardant Health | 4.02% | $770.82K | $23.86B | 182.94% | 61 Neutral | |
| Vertex Pharmaceuticals | 4.00% | $765.68K | $127.93B | 25.15% | 78 Outperform | |
| Agilent | 3.90% | $747.56K | $47.30B | 18.46% | 73 Outperform | |
| Thermo Fisher | 3.79% | $726.90K | $242.11B | 20.52% | 72 Outperform | |
| Dexcom | 3.74% | $717.17K | $32.21B | 27.31% | 79 Outperform | |
| Argenx Se | 3.51% | $672.05K | $57.44B | 14.90% | 79 Outperform |
GDOC Technical Analysis
Neutral
―
Price Trends
37.07
Negative
35.67
Positive
34.84
Positive
Market Momentum
-0.04
Positive
41.79
Neutral
10.53
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GDOC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 37.00, equal to the 50-day MA of 37.07, and equal to the 200-day MA of 34.84, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 41.79 is Neutral, neither overbought nor oversold. The STOCH value of 10.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GDOC.
GDOC Peer Comparison
Comparison Results
Performance Comparison
GDOC
Goldman Sachs Future Health Care Equity ETF
36.49
3.23
9.71%
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
LGHT
Langar Global HealthTech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents